Beginning with the approval of imatinib in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have transformed the therapeutic landscape for CML, for most patients turning a lethal disease into a chronic condition. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.